Loading provider…
Loading provider…
Internal Medicine Physician in San Francisco, CA
NPI: 1295792729Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get MD Emily's Phone Numberphone_androidMobile
Get MD Emily's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
1990 - 2026
CA State Medical License

American Board of Internal Medicine
Medical Oncology

National Board of Physicians and Surgeons
Medical Oncology
UCSF School of Medicine
medschool.ucsf.edu
Residency • Internal Medicine
1990 - 1992
Internship • Internal Medicine
1989 - 1990
University Of Minnesota Medical School
med.umn.edu
Medical School
Until 1989
University of California (San Francisco)/Fresno
Fellowship • Hematology and Medical Oncology
Until 1995
Immune enhancement of skin carcinogenesis by CD4+ T cells.
Authors: Daniel, Dylan, Meyer-Morse, Nicole, Bergsland, Emily K, Dehne, Kerstin, Coussens, Lisa M, Hanahan, Douglas
Journal: J Exp Med
Publication Date: 2003-04-14
Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
Authors: Fairooz Kabbinavar
Publication Date: 2005-06
Authors: Sarah Umetsu, Arie Perry, Sanjay Kakar, Nancy Joseph
Journal: Endocr Pathol
Publication Date: 2024-11-18
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Lu-177-DOTATATE, DRUG: Ga-68-DOTATATE, DRUG: F-18-FDG, DRUG: Amino Acid solution
Lead Sponsor: University of California, San Francisco
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: Paclitaxel, DRUG: Irinotecan
Lead Sponsor: Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: laboratory biomarker analysis, OTHER: pharmacological study, DRUG: dovitinib lactate